RareWays is a research directory. It helps you understand the science. It is not medical advice. Always discuss your care options with your healthcare team.
Coverage: 2020-01-01 onwards, with up to 300 results per query from PubMed and Europe PMC and separate limits on other sources. This is a selected index, not a complete literature search.
Updates are delayed or unverified. Check original sources for the latest information.
Your saved research and appointment questionsView recorded trial and retraction changes
Placenta Accreta Spectrum Disorder: Research Summary
Printed from RareWays (rareways.org)
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
Systemic inflammatory indices for predicting severe placenta accreta spectrum: a retrospective cohort study.
Lu Xiafen et al., Journal of global health (19 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42895275/
- 2.
CARLA-PEP: STREAMLINING PLACENTA ACCRETA SPECTRUM EVALUATION IN ABORTION CARE
J Fleisher et al., Contraception (16 October 2026)
https://doi.org/10.1016/j.contraception.2026.111649
- 3.
Evaluation of the uterine cavity, cervix and uterine blood flow after conservative surgical measures of the placenta accreta spectrum disorders (PAS- disorders).
, International Journal of Drug Delivery Technology (16 October 2026)
https://doi.org/10.25258/ijddt.16.72s.80
- 4.
KSMFM factsheet on obstetric complications after myomectomy or adenomyomectomy: uterine rupture and placenta accreta spectrum.
Pyeon Seung Yeon et al., Obstetrics & gynecology science (16 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42893824/
- 5.
Prospective Evaluation of Maternal Serum sFlt-1, PlGF, and the sFlt- 1/PlGF Ratio in Placenta Accreta Spectrum and Their Correlation With Placental Immunohistochemical Expression
Rahul Amitabh et al., Research Square (15 October 2026)
https://doi.org/10.21203/rs.3.rs-10262862/v1
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Placenta Accreta Spectrum Disorder
Placenta accreta spectrum is a pregnancy condition in which the placenta grows too deeply into the wall of the uterus and does not separate properly after birth. It can cause heavy bleeding and affect nearby organs. It is usually found by ultrasound or MRI during pregnancy. Care involves planned delivery, often by caesarean section with hysterectomy, in a specialist hospital team.
This overview is general information, not an individual medical assessment. Research is selected automatically and may include mismatches. How we select and explain research.
Most Recent Research
BACKGROUND: Placenta Accreta Spectrum (PAS) disorders are associated with substantial maternal morbidity, and distinguishing mild from severe forms prenatally remains difficult. Inflammatory indices derived from peripheral blood counts have emerged as promising biomarkers, yet their role in grading PAS severity has been insufficiently investigated. This study aimed to assess the discriminative value of the systemic immune-inflammation index (SII), systemic inflammation response index (SIRI), and other inflammatory indices for differentiating severe from mild PAS within an already diagnosed PAS population in late pregnancy. METHODS: This retrospective single-centre cohort study included 1,276 patients with histopathologically confirmed PAS. Third-trimester neutrophil, lymphocyte, monocyte, and platelet counts were used to derive neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), SII, and SIRI. Multivariable logistic regression, receiver operating characteristic curve analysis, and decision curve analysis (DCA) were conducted. RESULTS: Compared with the mild PAS group (n = 1,060), the severe PAS group (n = 216) showed significantly lower SIRI, SII, NLR, and PLR values (all P < 0.001). SIRI demonstrated moderate discriminative performance (area under the curve = 0.712). DCA suggested its potential clinical usefulness across threshold probabilities. CONCLUSIONS: Lower third-trimester SIRI, SII, NLR, and PLR values are associated with severe PAS. SIRI shows moderate diagnostic performance and may serve as a cost-effective adjunct to imaging for prenatal risk stratification. Prospective validation is warranted.
Common Questions
What is Placenta Accreta Spectrum Disorder?
Placenta accreta spectrum is a pregnancy condition in which the placenta grows too deeply into the wall of the uterus and does not separate properly after birth. It can cause heavy bleeding and affect nearby organs. It is usually found by ultrasound or MRI during pregnancy. Care involves planned delivery, often by caesarean section with hysterectomy, in a specialist hospital team.
How many clinical trials are available for Placenta Accreta Spectrum Disorder?
RareWays currently indexes 67 clinical trials for Placenta Accreta Spectrum Disorder, of which 5 are actively recruiting. These counts cover indexed trials across countries, not just your country. An Australian site does not necessarily mean that site is recruiting. Check locations, eligibility and current availability with the study team.
Where does the research data for Placenta Accreta Spectrum Disorder come from?
RareWays aggregates research from PubMed, Europe PMC, OpenAlex, and ClinicalTrials.gov. Data is refreshed automatically every day. All articles and trials link directly to their original sources.
Get research updates
Monthly email when new findings are published for Placenta Accreta Spectrum Disorder.
Your email and selected disease are stored for these updates. Unsubscribe any time. Privacy and deletion.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.